Website
News25/Ratings2
Latest news
25 items- PRTotus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial OfficerEMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said
- 13D/GSEC Form SC 13G/A filed by Calyxt Inc. (Amendment)SC 13G/A - Cibus, Inc. (0001705843) (Subject)
- SECCalyxt Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Cibus, Inc. (0001705843) (Filer)
- INSIDERRiggs Rory B converted options into 1,500,000 shares and acquired 1,505,967 units of Class B Common Stock, increasing direct ownership by 128% to 3,103,788 units (SEC Form 4)4 - Cibus, Inc. (0001705843) (Issuer)
- SECCalyxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Cibus, Inc. (0001705843) (Filer)
- SECSEC Form 424B5 filed by Calyxt Inc.424B5 - Cibus, Inc. (0001705843) (Filer)
- SECCalyxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Cibus, Inc. (0001705843) (Filer)
- INSIDERRiggs Rory B disposed of 39,476 shares and bought $5,470,992 worth of shares (517,107 units at $10.58), increasing direct ownership by 47% to 1,622,495 units (SEC Form 4)4 - Cibus, Inc. (0001705843) (Issuer)
- SECCalyxt Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Cibus, Inc. (0001705843) (Filer)
- SECSEC Form 424B5 filed by Calyxt Inc.424B5 - Cibus, Inc. (0001705843) (Filer)
- SECCalyxt Inc. filed SEC Form 8-K: Other Events8-K - Cibus, Inc. (0001705843) (Filer)
- SECSEC Form 424B5 filed by Calyxt Inc.424B5 - Cibus, Inc. (0001705843) (Filer)
- SECCalyxt Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Cibus, Inc. (0001705843) (Filer)
- SECSEC Form 10-Q filed by Calyxt Inc.10-Q - Cibus, Inc. (0001705843) (Filer)
- SECCalyxt Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Cibus, Inc. (0001705843) (Filer)
- SECCalyxt Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Cibus, Inc. (0001705843) (Filer)
- SECSEC Form 424B3 filed by Calyxt Inc.424B3 - Cibus, Inc. (0001705843) (Filer)
- SECSEC Form EFFECT filed by Calyxt Inc.EFFECT - Cibus, Inc. (0001705843) (Filer)
- SECSEC Form S-3/A filed by Calyxt Inc. (Amendment)S-3/A - Cibus, Inc. (0001705843) (Filer)
- SECCalyxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - Cibus, Inc. (0001705843) (Filer)
- SECCalyxt Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Other Events, Leadership Update8-K - Cibus, Inc. (0001705843) (Filer)
- INSIDERSEC Form 3: New insider Collins James C. Jr. claimed no ownership of stock in the company3 - Cibus, Inc. (0001705843) (Issuer)
- SECCalyxt Inc. filed SEC Form 8-K: Leadership Update8-K - Cibus, Inc. (0001705843) (Filer)
- SECCalyxt Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Cibus, Inc. (0001705843) (Filer)
- SECSEC Form 10-Q filed by Calyxt Inc.10-Q - Cibus, Inc. (0001705843) (Filer)